📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML. (2018)

First Author: Anderson E

Attributed to: MICA: Development of a rapid in-vitro multi-drug test device to predict response to combined drug chemotherapy in leukaemia patients, before treatment funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.leukres.2018.08.007

PubMed Identifier: 30119908

Publication URI: http://europepmc.org/abstract/MED/30119908

Type: Journal Article/Review

Volume: 74

Parent Publication: Leukemia research

ISSN: 0145-2126